(Q34783592)

4 August 2017

1 reference

title

Farnesyl transferase inhibitors as anticancer agents (English)

1 reference

4 August 2017

2

G K Dy

1 reference

4 August 2017

P Haluska

1

1 reference

4 August 2017

A A Adjei

series ordinal

3

1 reference

4 August 2017

publication date

1 September 2002

1 reference

European Journal of Cancer

4 August 2017

published in

1 reference

4 August 2017

volume

38

1 reference

4 August 2017

issue

13

1 reference

4 August 2017

page(s)

1685-1700

1 reference

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Evidence for a catalytic role of zinc in protein farnesyltransferase. Spectroscopy of Co2 -farnesyltransferase indicates metal coordination of the substrate thiolate

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Enzymatic modification of proteins with a geranylgeranyl isoprenoid

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

p21ras is modified by a farnesyl isoprenoid

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

cDNA cloning of the two subunits of human CAAX farnesyltransferase and chromosomal mapping of FNTA and FNTB loci and related sequences

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The prenylation of proteins

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Posttranslational modification of proteins by isoprenoids in mammalian cells

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Direct identification of palmitic acid as the lipid attached to p21ras

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Ras biochemistry and farnesyl transferase inhibitors: a literature survey

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent Manner

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

BH3 Domain of BAD Is Required for Heterodimerization with BCL-XL and Pro-apoptotic Activity

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Protein prenylation: molecular mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Protein isoprenylation and methylation at carboxyl-terminal cysteine residues

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Friends and family: the role of the Rab GTPases in vesicular traffic

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

PRL-1 PTPase expression is developmentally regulated with tissue-specific patterns in epithelial tissues.

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Prenyl group identification of rap2 proteins: a ras superfamily member other than ras that is farnesylated

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Characterization of HDJ-2, a human 40 kD heat shock protein

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Human DnaJ homologs dj2 and dj3, and bag-1 are positive cochaperones of hsc70

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Human adrenoleukodystrophy protein and related peroxisomal ABC transporters interact with the peroxisomal assembly protein PEX19p

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

The gamma subunit of transducin is farnesylated

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

Farnesylcysteine, a constituent of the alpha and beta subunits of rabbit skeletal muscle phosphorylase kinase: localization by conversion to S-ethylcysteine and by tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(02)00166-1

7 January 2021

10.1016/S0959-8049(02)00166-1

Identifiers

DOI

1 reference

4 August 2017

1 reference